drugset / Trial / NCT03082755
Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease
Phase 4
Recruiting
156 enrolled
University of Texas at Austin
National Institute on Aging (NIA) · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Nighttime agitation in persons with Alzheimer's disease causes patient suffering, distresses caregivers, and often results in prescriptions for harmful antipsychotics. Effective treatments are lacking because of limited knowledge of the etiology of nighttime agitation. The investigators propose a clinical trial to better elucidate whether a sleep disorder, restless legs syndrome, may be a mechanism for nighttime agitation, and if treatment with gabapentin enacarbil (Horizant®) reduces nighttime agitation, improves sleep, reduces restless legs syndrome behaviors, and reduces antipsychotic medications.
Timeline
- Start
- 2017-07-01
- Primary completion
- 2022-08-31
- Completion
- 2023-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | gabapentin enacarbil | Small molecule | 300 mg | Oral |
| Subject | gabapentin enacarbil | Small molecule | 600 mg | Oral |